ALK licenses rights to neffy, an adrenaline nasal spray for emergency treatment of anaphylaxis EP News Bureau Nov 12, 2024 ALK also gains rights to future indications, including acute urticaria flares (in development)
ARS Pharmaceuticals’ Neffy poised to disrupt epinephrine market as first needle-free nasal spray:… EP News Bureau Oct 1, 2024 Neffy set to challenge injectable epinephrine devices with needle-free ease, but faces hurdles in proving real-world effectiveness…
